|
Apexigen Inc. (Privately Held) |
|
|
April 20, 2012 Issue |
||
|
The Most Powerful Name In Corporate News and Information |
||
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | SERVICES | HOME PAGE |
||
|
Apexigen Inc. is Using Antibodies Derived from Rabbits to Develop Therapies in Cancer and Inflammatory Disease |
||
|
Apexigen, Inc. is a
privately held, biopharmaceutical company focused on the development and
commercialization of innovative therapeutic monoclonal antibodies for the
treatment of diseases with unmet medical needs. Apexigen’s product pipeline
includes 7 humanized antibodies derived from its proprietary antibody
technology platform. Collaborations are a key element of Apexigen’s business
model with 6 collaborations currently in place. The company’s core
advantages are its proprietary technology platform and expertise translating
the unique therapeutic benefits of humanized rabbit monoclonal antibodies.
President, Chief Executive
Officer, and a member of Board of Directors. He has over 15 years of
research and development experience in the biotech industry, primarily in
the areas of monoclonal antibody and siRNA based therapeutics. Prior to joining Apexigen, Dr. Yang was Vice President, Research and Preclinical Development at Intradigm Corporation which was acquired by Silence Therapeutics in 2009. In this role, he was responsible for overseeing the progress of company’s discovery and preclinical development of RNAi-based therapeutics.
Dr. Yang received his medical degree from Beijing Medical University. He was awarded his doctorate in Immunology from University of Bern in Switzerland. Dr. Yang was a postdoctoral fellow at Novartis and Stanford University School of Medicine. |
|
|
|
Interview conducted by: Lynn Fosse, Senior Editor, CEOCFO Magazine, Published - April 20, 2012
Dr. Yang: The idea is to develop innovative and Best-in-Class antibody therapeutics. Many companies claim they can do therapeutic antibodies. However, we believe our technology will enable us and our partners to discover and develop unique and superb antibody therapeutics.
Dr. Yang: Antibodies have become one of the major therapeutic modalities in modern therapy for inflammation and cancer. There have been many different ways to make antibodies, which are a part of our immune system and a very important component to our immune defense against any infectious agents. We are taking advantage of antibodies as part of natural components of our immune system against cancer and some of the important components of inflammation and inflammatory disease. At Apexigen we are using a very unique approach where we can make therapeutic antibodies from rabbits. The reason we pick rabbit as the source of our antibodies is that the way the rabbit makes antibodies is different from humans and any other species like rodents. More importantly, the antibody, as a therapeutic coming from a rabbit source, has higher specificity, potency and the potential to translate to higher efficacy. We have data to show that antibodies derived from rabbits have unique characteristics and we are translating those characteristics to potential therapeutic benefits.
Dr. Yang: The first generation of therapeutic antibodies came from mice and it took about twenty years for scientists to figure out a way to make the mouse’s antibody more like a human’s. That is the process called “humanization”. People were also trying to do it from rabbits as well because it has been known for decades that rabbit antibodies are more stable and specific, and have other characteristics that are more suitable for therapeutic use. However, people were not able to make monoclonal antibodies from rabbits. The reason behind this is that there was lack of technology to make the antibody producing cells to live longer outside of animals to produce enough antibodies to do the pharmacology studies. Therefore, in 1996 a scientist at Loyola University, Katherine Knight, discovered myeloma cells from rabbits by generating transgenic rabbits. These myeloma cells allow people to create monoclonal antibody producing hybridoma cells from rabbits. Then it took about ten years to improve these technologies to the current levels, where now we can make rabbit monoclonal antibodies robustly and quickly. To convert rabbit antibody to human therapeutics we have developed a proprietary humanization technology that is designed specifically for humanizing rabbit antibodies. These are two fundamental technologies for developing therapeutic antibodies from rabbits. The technologies have become more and more mature and robust for various applications and commercialization. Now we are expanding the utility of our technologies to develop more innovative therapeutic products.
Dr. Yang: We are focusing on two areas. One is cancer and the second one is inflammatory diseases, because these two areas have the most unmet medical need, especially oncology. There is a huge effort from many pharma and biotech companies to develop oncology drugs, but many of the approved cancer drugs are barely making incremental improvements. Patients need more potent and efficacious therapies and we believe that our technologies may revolutionize antibody therapy for oncology as well as other diseases such as inflammation. If you look at our pipeline, we have 7 humanized antibody product candidates. These antibodies primarily are targeting cancers and there are 2 or 3 out of 7 of these against inflammation. Some of the antibodies may actually work in both indications and we are in the process of advancing some of the key programs into the human clinical trials. For instance, we are developing our own product candidate APX005, an antibody against CD40 primarily for oncology indications.
Dr. Yang: Our strategy is that, on one hand we are developing our own products, because that is a key driver for increasing value of the company. On the other hand, we have the capability and the technology to make multiple new antibodies within a very short period. Therefore, we are very actively looking for partners to use our technology. We already have six partners working with us. Two of them are multinational large pharma companies. We signed a deal with Janssen Biotech, a Johnson & Johnson company, in December 2010. This collaboration enables Janssen Biotech to use our technology to develop antibodies against their own targets. We have another undisclosed collaboration with another multinational big pharma company working on another antibody for a different indication and they received IND approval to start clinical trials last December. These are the two technology licensing partnerships, where they use our technology to develop their own antibody compounds. There is another type of collaboration we call “product collaboration”. In that area we have four partnerships that are primarily in China. One is with Simcere Pharmaceuticals, which is listed on the New York Stock Exchange. We collaborate with Simcere on an antibody against VEGF for oncology. We have a second collaboration with 3SBio, which is another Chinese biopharmaceutical company listed on Nasdaq. We are collaborating on antibody against TNF. The third one is T-Mab Biotechnology. We are collaborating on an antibody against IL1-beta. Very recently on March 6, 2012, we signed another partnership deal with another Chinese pharmaceutical company Shanghai Duyiwei, where we are working together on an antibody against VEGF Receptor 2. Although as a young company with 6 collaborations in place, we are still actively looking for more collaborations in both areas of product as well as technology collaborations.
Dr. Yang: It is very challenging I have to admit because our number-one priority or focus is to develop our own product. The collaborations help us to validate our technology and help us to generate revenue. As you know, the current economic and investment environment is tough for start-up companies, so we cannot totally rely on the funding from VCs. We have to maximize the value of our products and technology first. Ideally, that will support some of our product development efforts and increase the value of the company. It is a fine balance, because we need both. We cannot just focus on our own product development, because it is very costly and requires significant capital. We spend approximately half of our time on product development and the other half on building new partnerships. Finally, yet importantly, we also spend time working with our partners because some of them do not have a lot of experience in developing antibody therapeutics. Therefore, we have to work together.
Dr. Yang:
We are a company with multiple opportunities. We have our own product
candidate, APX005, an anti-CD40 antibody for the treatment of pancreatic
cancer and other malignancies. The proof of concept for anti-CD40 antibody
in cancer has been done in humans. It has been demonstrated that an
anti-CD40 antibody has efficacy in treating patients with pancreatic
cancers. Therefore, we are very excited about the potential of APX005.
Secondly, we have technologies that enable not only ourselves but also our
partners to make innovative antibody therapeutics very rapidly. The third
one is our product pipeline. We already licensed 4 candidates to our
partners in China. Most of them only have the rights in China, so we retain
the global rights outside China. If they develop products in China and
demonstrate the desired safety and efficacy profiles in clinical trials, we
can either develop the candidates outside China by ourselves or collaborate
with other companies to advance the program forward. Our management team is
highly competent and experienced in both areas of antibody drug development
and partnerships, so we know well how to manage the product development as
well as partnership alliances. We can create multiple opportunities for our
shareholders and investors and these opportunities are synergistic in a way
that the partnerships will help us further validate our products and
technology. In the mean time, we generate revenues to support our company
and support our product development. Of course, the major value driver is
our own product development. We are not just a single opportunity company.
We have multiple shots on goal for creating value for our shareholders and
investors. Therefore, we are very confident that we can succeed in building
a value-creating business. More importantly, we can bring innovative
therapeutics to patients who have unmet medical needs. |
||
|
We are a company with multiple opportunities. - Xiaodong Yang |
||
|
|
||
|
|
||
